“Today’s patients are living longer, more active lives, with high expectations for their health and quality of life, so lifetime management of heart valve disease, starting with the first valve, is increasingly important,” said Professor Ivan Casserly, consultant cardiologist at the Mater Misericordiae University Hospital, Dublin. “SAPIEN 3 Ultra RESILIA gives these patients a promising option, as RESILIA tissue’s calcium-blocking technology addresses structural valve deterioration, one of the primary causes of reintervention following heart valve replacement.”

Edwards RESILIA is a bovine pericardial tissue treated with advanced anti-calcification technology that provides the potential to extend the durability of the SAPIEN 3 Ultra RESILIA valve.

RESILIA tissue is already used in the Edwards INSPIRIS RESILIA valve. Recent data on the RESILIA tissue from the seven-year COMMENCE Study showed encouraging results with low rates of structural valve deterioration (99.3 per cent freedom from structural valve deterioration), clinically stable gradients and freedom from reoperation (97.2 per cent).